Novo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Novo Nordisk said on Tuesday a large study had shown its highly effective obesity drug Wegovy also had a clear cardiovascular benefit, boosting the Danish drugmaker’s hopes of moving beyond Wegovy’s image as a lifestyle drug.
That’s significantly better than the 15-17% expected by investors and analysts ahead of the eagerly awaited data.The study, called SELECT, involved 17,500 overweight or obese people with a history of heart disease aged 45 years or older with no prior history of diabetes.The news sent shares in Europe’s second-most valuable listed company after LVMH up more than 13% to record highs.The results may help persuade insurers in the U.S.
“I suspect that medical claims savings from this are years away,” said Dr. Jeff Levin-Scherz, a consultant at Willis Towers Watson, which advises employers on benefits.He said the drugs at best may prove to be cost effective in terms of improving patients’ lives, rather than lowering their total cost of care.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Les mer »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Les mer »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Les mer »
Novo Nordisk hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%Shares of Novo Nordisk reached record highs after a study revealed that its Wegovy treatment reduced the risk of heart issues by 20%. The positive results have generated excitement among investors and healthcare professionals.
Les mer »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Les mer »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20%, Trial Says—Novo Nordisk Shares SurgeThe weight-loss drug Wegovy has been found to reduce the risk of major heart disease by 20%, according to a trial conducted by Novo Nordisk. The positive results of the trial have caused a surge in Novo Nordisk's shares, with an increase of over 16%.
Les mer »